Tuesday, December 21, 2021
2:32 PM EST – Entheon Biomedical Corp. : Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc., is now available for sale in Canada and the United States. Entheon, a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, via its Subsidiary HaluGen Life Sciences, has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca. Entheon Biomedical Corp
(C.ENBI) shares were down $0.03 at 0.39.
Stocks in Play: Entheon Biomedical Corp., Tue, 21 Dec 2021 02:42:06 EST